Alere NMP22®
Healthy individuals generally have very small amounts of NMP22 protein in the urine. However, the level of NMP22 protein is often elevated in the urine of patients with bladder cancer, even at early stages of the disease.1 The Alere NMP22® Test is an enzyme immunoassay for the quantitative determination of nuclear mitotic apparatus protein (NuMA) in stabilized voided urine. NuMA is an abundant component of the nuclear matrix proteins (NMP22). The Alere NMP22® BladderChek® Test is the only in-office test approved by the FDA as an aid in the diagnosis and monitoring of bladder cancer in conjunction with standard diagnostic procedures. Both assays are painless and non-invasive and detect elevated levels of NMP22 protein.
1. Mostafid H et al. BJU Int 2010; 105: 585–8.
Products
Searching for Results
Quit For Life® Program
Our Quit For Life® Program, offered in collaboration with the American Cancer Society, is the nation’s leading tobacco cessation service. It is designed to help participants overcome their physical, psychological, and behavioral addiction to tobacco through a combination of medicine, web-based education, and behavioral coaching provided by a highly-trained Quit Coach® counselor. The program has a quit rate of 45%, which is more than triple the industry standard. 93% of participants also expressed satisfaction with our methods and service levels—far surpassing the industry standard.
Learn More
All Wellness Solutions
In order to provide clients with state of the art care, Alere has developed Wellness Solutions, which combine the latest in technology, services, and research in order to treat clients holistically. These solutions are listed below.
English